Copyright
©The Author(s) 2016.
World J Gastroenterol. Apr 14, 2016; 22(14): 3803-3812
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3803
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3803
Figure 4 Overall survival rate of the low-dose hepatocellular carcinoma group and high-dose hepatocellular carcinoma group after adjustment with propensity scores among hepatocellular carcinoma patients who met the Milan criteria (A) and did not meet the Milan criteria (B).
HBIG: Hepatitis B Immunoglobulin.
- Citation: Lee EC, Kim SH, Lee SD, Park H, Lee SA, Park SJ. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol 2016; 22(14): 3803-3812
- URL: https://www.wjgnet.com/1007-9327/full/v22/i14/3803.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i14.3803